Search

Your search keyword '"Anxionnat R"' showing total 8 results
Start Over Author "Anxionnat R" Database OpenAIRE
8 results on '"Anxionnat R"'

1. EmboASSIST a new software to help endovascular treatment of brain AVMs

Author

Anxionnat, R, Djebiret, Y, Kerrien, Erwan, Berger, Marie-Odile, Cartier, I, Amelot, S, Trousset, Y, Bracard, S, Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Recalage visuel avec des modèles physiquement réalistes (TANGRAM), Inria Nancy - Grand Est, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Department of Algorithms, Computation, Image and Geometry (LORIA - ALGO), Laboratoire Lorrain de Recherche en Informatique et ses Applications (LORIA), Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire Lorrain de Recherche en Informatique et ses Applications (LORIA), Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institut National de Recherche en Informatique et en Automatique (Inria), General Electric Medical Systems [Buc] (GE Healthcare), and General Electric Medical Systems

Subjects
[INFO.INFO-IM]Computer Science [cs]/Medical Imaging, [INFO.INFO-CV]Computer Science [cs]/Computer Vision and Pattern Recognition [cs.CV]
Abstract

International audience; EmboASSIST (GE Healthcare) is a new 3D visualization software dedicated to assist AVM embolization. It provides a one-click 3D segmentation of vascular anatomy from CBCT acquisition then dynamically track feeders and simulate virtual injections. These segmented feeders can be displayed on live fluoroscopy facilitating micro catheter navigation. Moreover, 3D MR acquisition may be automatically registered with CBCT acquisition and also displayed on live fluoroscopy.

Published
2022

2. Endovascular therapy with or without intravenous thrombolysis in acute stroke with tandem occlusion

Author

Anadani, M. Marnat, G. Consoli, A. Papanagiotou, P. Nogueira, R.G. Spiotta, A.M. Bourcier, R. Kyheng, M. Labreuche, J. Siddiqui, A.H. Ribo, M. De Havenon, A. Fischer, U. Sibon, I. Dargazanli, C. Arquizan, C. Cognard, C. Olivot, J.M. Anxionnat, R. Audibert, G. Mazighi, M. Blanc, R. Lapergue, B. Richard, S. Gory, B.

Abstract

Background: Endovascular therapy (EVT) is effective and safe in patients with tandem occlusion. The benefit of intravenous thrombolysis (IVT) prior to EVT in acute tandem occlusion is debatable. Objective: To compare EVT alone with EVT plus IVT in patients with acute ischemic stroke due to anterior circulation tandem occlusions. Methods: This is an individual patient pooled analysis of the Thrombectomy In TANdem lesions (TITAN) and Endovascular Treatment in Ischemic Stroke (ETIS) Registries. Patients were divided into two groups based on prior IVT treatment: (1) IVT+ group, which included patients who received IVT prior to EVT, (2) IVT- group, which included patients who did not receive IVT prior to EVT. Propensity score (inverse probability of treatment weighting (IPTW)) was used to reduce baseline between-group differences. The primary outcome was favorable outcome - that is, modified Rankin Scale (mRS) score 0 to 2 at 90 days. Results: Overall, 602 consecutive patients with an acute stroke with tandem occlusion were included (380 and 222 in the bridging therapy and EVT alone groups, respectively). Onset to imaging time was shorter in the IVT+ group (median 103 vs 140 min). In contrast, imaging to puncture time was longer in the IVT+ group (median 107 vs 91 min). In IPTW analysis, the IVT+ group had higher odds of favorable outcome, excellent outcome (90-day mRS score 0-1), and successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2b/3 at the end of EVT). There was no difference in the risk of significant hemorrhagic complications between groups. In secondary analysis of patients treated with acute cervical internal carotid artery stenting, bridging therapy was associated with higher odds of favorable outcome and lower odds of mortality at 90 days. Conclusions: Our results suggest that bridging therapy in patients with acute ischemic stroke due to anterior tandem occlusion is safe and may improve functional outcome, even in the setting of acute cervical internal carotid artery stenting during EVT. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Published
2021

3. Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

Author

Kremer, S. (Stéphane), Boulay, C. (Clotilde), de Sèze, J. (Jérome), Ferré, J. (Jean-Christophe), Maamar, A. (Adel), Carsin-Nicol, B. (Béatrice), Collange, O. (Olivier), Bonneville, F. (Fabrice), Adam, G. (Gilles), Martin-Blondel, G. (Guillaume), Rafiq, M. (Marie), Geeraerts, T. (Thomas), Delamarre, L. (Louis), Grand, S. (Sylvie), Krainik, A. (Alexandre), Kremer, S. (Stephane), Alleg, M. (Manel), Anheim, M. (Mathieu), Anxionnat, R. (René), Ardellier, F. (François-Daniel), Baloglu, S. (Seyyid), Bapst, B. (Blanche), Benzakoun, J. (Joseph), Berge, J. (Jérome), Bolognini, F. (Federico), Bornet, G. (Grégoire), Boulouis, G. (Grégoire), Boutet, C. (Claire), Brisset, J. (Jean Christophe), Caillard-ohlmann, S. (Sophie), Carré, S. (Sophie), Comby, P. (Pierre-Olivier), Constans, J. (Jean Marc), David, J. (Jean-Stéphane), de Beaurepaire, I. (Isaure), De Seze, J. (Jerome), Desal, H. (Hubert), Edjlali-Goujon, M. (Myriam), Fabre, X. (Xavier), Fafi-Kremer, S. (Samira), Feuerstein, P. (Philippe), Henry Feugeas, M. (Marie-Cécile), Forestier, G. (Géraud), Gaudemer, A. (Augustin), Hansmann, Y. (Yves), Heintz, A. (Adrien), Boisrame, J. (Julie), Hemmert, C. (Céline), Hmeydia, G. (Ghazi), Jager, L. (Lavinia), Kazémi, A. (Apolline), Kerleroux, B. (Basile), Khalil, A. (Antoine), Lacalm, A. (Audrey), Lecler, A. (Augustin), Lecocq, C. (Claire), Lefebvre, N. (Nicolas), Lersy, F. (François), Matthieu, M. (Muriel), Megdiche, I. (Imen), Mertes, P. (Paul-michel), Messié, J. (Julien), Metanbou, S. (Serge), Meyer, N. (Nicolas), Meziani, F. (Ferhat), Mutschler, V. (Veronique), Nesser, P. (Patrick), Oesterlé, H. (Hélène), Ohana, M. (Mickaël), Oppenheim, C. (Catherine), Pyatigorskaya, N. (Nadya), Ricolfi, F. (Frédéric), Saleme, S. (Suzana), Schenck, M. (Maleka), Schmitt, E. (Emmanuelle), Schneider, F. (Francis), Sebag, N. (Nathan), Talla Mba, Y. (Yannick), Thouant, P. (Pierre), Willaume, T. (Thibault), Zhu, F. (François), Zorn, P. (Pierre-Emmanuel), Cotton, F. (François), Les Hôpitaux Universitaires de Strasbourg (HUS), Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Radiologie [CHU de Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], CHU Toulouse [Toulouse], CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre hospitalier de Haguenau, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nancy (CHU Nancy), CHU Henri Mondor, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), CHU Bordeaux [Bordeaux], Hôpitaux Civils de Colmar, Hôpital Privé d'Antony, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Observatoire Français de la Sclérose En Plaques [Lyon] (OFSEP), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Amiens-Picardie, Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier de Roanne (CH Roanne), CH de Roanne, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Limoges, CHU Strasbourg, Nouvel Hôpital Civil de Strasbourg, Université de Strasbourg (UNISTRA), Hôpital Marie-Madeleine [Forbach], CHU Lille, Hôpital de la Fondation Ophtalmologique Adolphe de Rothschild [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Les Hôptaux universitaires de Strasbourg (HUS), Nanomédecine Régénérative (NanoRegMed), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Henri Mondor [Créteil], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Ferré, Jean-Christophe, and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, medicine.medical_specialty, Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC], Adolescent, Pneumonia, Viral, Gastroenterology, 030218 nuclear medicine & medical imaging, Temporal lobe, White matter, Cohort Studies, 03 medical and health sciences, symbols.namesake, Betacoronavirus, Young Adult, 0302 clinical medicine, Cerebrospinal fluid, Internal medicine, Intensive care, medicine, Humans, Radiology, Nuclear Medicine and imaging, 10. No inequality, Child, Pandemics, Fisher's exact test, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, SARS-CoV-2, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, Brain, COVID-19, Retrospective cohort study, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, 3. Good health, Venous thrombosis, medicine.anatomical_structure, Neuroradiology, 030220 oncology & carcinogenesis, symbols, Female, business, Coronavirus Infections
Abstract

International audience; BackgroundBrain MRI parenchymal signal abnormalities have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).PurposeTo describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe coronavirus disease 2019 (COVID-19) infection.Materials and MethodsThis was a retrospective study of patients evaluated from March 23, 2020, to April 27, 2020, at 16 hospitals. Inclusion criteria were (a) positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays, (b) severe COVID-19 infection defined as a requirement for hospitalization and oxygen therapy, (c) neurologic manifestations, and (d) abnormal brain MRI findings. Exclusion criteria were patients with missing or noncontributory data regarding brain MRI or brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using the Fisher exact test. Quantitative data were compared using the Student t test or Wilcoxon test. P < .05 represented a significant difference.ResultsThirty men (81%) and seven women (19%) met the inclusion criteria, with a mean age of 61 years ± 12 (standard deviation) (age range, 8–78 years). The most common neurologic manifestations were alteration of consciousness (27 of 37, 73%), abnormal wakefulness when sedation was stopped (15 of 37, 41%), confusion (12 of 37, 32%), and agitation (seven of 37, 19%). The most frequent MRI findings were signal abnormalities located in the medial temporal lobe in 16 of 37 patients (43%; 95% confidence interval [CI]: 27%, 59%), nonconfluent multifocal white matter hyperintense lesions seen with fluid-attenuated inversion recovery and diffusion-weighted sequences with variable enhancement, with associated hemorrhagic lesions in 11 of 37 patients (30%; 95% CI: 15%, 45%), and extensive and isolated white matter microhemorrhages in nine of 37 patients (24%; 95% CI: 10%, 38%). A majority of patients (20 of 37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation and a higher admission rate in intensive care units (20 of 20 patients [100%] vs 12 of 17 patients without hemorrhage [71%], P = .01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%] vs 11 of 17 patients [65%], P = .005). Only one patient had SARS-CoV-2 RNA in the cerebrospinal fluid.ConclusionPatients with severe coronavirus disease 2019 and without ischemic infarcts had a wide range of neurologic manifestations that were associated with abnormal brain MRI scans. Eight distinctive neuroradiologic patterns were described.

Published
2020
Full Text
View/download PDF

4. Standards of practice in acute ischemic stroke intervention: international recommendations

Author

Pierot, L., Jayaraman, M.V., Szikora, I., Hirsch, J.A., Baxter, B., Miyachi, S., Mahadevan, J., Chong, W., Mitchell, P.J., Coulthard, A., Rowley, H.A., Sanelli, P.C., Tampieri, D., Brouwer, P.A., Fiehler, J., Kocer, N., Vilela, P., Rovira, A., Fischer, U., Caso, V., Worp, B. van der, Sakai, N., Matsumaru, Y., Yoshimura, S., Anxionnat, R., Desal, H., Biscoito, L., Pumar, J.M., Diaz, O., Fraser, J.F., Linfante, I., Liebeskind, D.S., Nogueira, R.G., Hacke, W., Brainin, M., Yan, B., Soderman, M., Taylor, A., Pongpech, S., Tanaka, M., Karel, T., AAFITN, Australian New Zealand Soc, Amer Soc Neuroradiology ASNR, Canadian Soc Neuroradiology, ESMINT, European Soc Neuroradiology, ESO, JSNET, French Soc Neuroradiology SFNR, Ibero-Latin Amer Soc Diagnostic, SNIS, SVIN, WSO, World Federation Interventional, İÜC, Centre Hospitalier Universitaire de Reims (CHU Reims), Hémostase et Remodelage Vasculaire Post-Ischémie (HERVI - EA 3801), Université de Reims Champagne-Ardenne (URCA), Brown University, Providence, Rhode Island, Centre hospitalier universitaire de Nantes (CHU Nantes), Chiba University [Japan], and Toronto Western Hospital

Subjects
medicine.medical_specialty, Neurology, medicine.medical_treatment, Acute ischemic stroke, MEDLINE, 030204 cardiovascular system & hematology, Article, 030218 nuclear medicine & medical imaging, law.invention, mechanical thrombectomy, 03 medical and health sciences, 0302 clinical medicine, Neuroimaging, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Randomized controlled trial, law, Intervention (counseling), medicine, Humans, Radiology, Nuclear Medicine and imaging, standards of practice, Stroke, ComputingMilieux_MISCELLANEOUS, Thrombectomy, Neuroradiology, business.industry, General Medicine, Thrombolysis, medicine.disease, stroke, Clinical neurology, 3. Good health, Mechanical thrombectomy, Emergency medicine, Surgery, Neurology (clinical), Medical emergency, emergent large vessel occlusion, business, 030217 neurology & neurosurgery, Large vessel occlusion
Abstract

After the five positive randomized controlled trials showing the benefit of mechanical thrombectomy (MT) in the management of acute ischemic stroke (AIS) with emergent large vessel occlusion (ELVO), a multisociety meeting was organized during the 16th Congress of the World Federation of Interventional and Therapeutic Neuroradiology (WFITN), October 2015, Gold Coast (Australia). This meeting was dedicated to the training of physicians performing MT, and recommendations were published thereafter in multiple scientific journals.1 The same group of scientific societies decided to organize a similar meeting during the 17th WFITN Congress, October 2017, Budapest (Hungary). This multisociety meeting was dedicated to standards of practice in acute ischemic stroke intervention (AISI), aiming for a consensus on the minimum requirements for centers providing such treatment. In an ideal situation, all patients would be treated at a center offering a full spectrum of neuroendovascular care (a level 1 center). However, for geographical reasons, some patients are unable to reach such a center in a reasonable period of time. With this in mind, the group paid special attention to define recommendations on the prerequisites of organizing stroke centers providing MT for AIS, but not for other neurovascular diseases (a level 2 center). Finally, some centers will have a stroke unit and offer intravenous thrombolysis, but not any endovascular stroke therapy (a level 3 center). Together, these level 1, 2, and 3 centers form a complete stroke system of care. The requirements for these centers are summarized in table 1. View this table: Table 1 General summary of capabilities of level 1, 2, and 3 centers Due to the relatively short time elapsed since the evidence in favor of MT has been published, some organizational aspects still require scientific validation. However, considering the extremely fast growth of such activities around the world, the multisociety group considered it timely and rational to set-up recommendations and a framework for …

Published
2018
Full Text
View/download PDF

5. P-35 Leucoaraïose : comparaison des séquences T2 et flair et corrélations avec l’état neurocognitif

Author

Serge Bracard, L. Picard, Stéphane Kremer, Faiez Zannad, J.M. Virion, Emmanuelle Schmitt, and Anxionnat R. Kearney-Schwartz

Subjects
Radiological and Ultrasound Technology, Radiology, Nuclear Medicine and imaging, Neurology (clinical)
Abstract

Objectifs Comparer les sequences FLAIR et T2 pour l’evaluation de la leucoaraiose et etablir des correlations avec l’etat neurocognitif des patients. Materiels et methodes 145 patients de plus de 60 ans, hypertendus traites, exempt de demence (MMS > 23) de depression et d’antecedent d’AVC ont ete etudies par IRM (Signa 1,5 T GEMS) en sequences T2, Flair et Diffusion dans le cadre de l’etude ADELAHYDE (CIC-INSERM) portant sur l’evaluation des facteurs de risques du vieillissement cerebral. Les hypersignaux de la substance blanche ont ete analyses et cotes separement en fonction de leur localisation et de leur etendue : periventriculaires (cornes frontales et occipitales, corps ventriculaires, fornix), et substance blanche profonde. Resultats La sequence FLAIR apparait legerement superieure pour la mise en evidence des hypersignaux de la substance blanche periventriculaire et en particulier pour les anomalies de signal du fornix (37,1 % en Flair contre 15,2 % en T2). Aucune difference significative n’a ete notee entre les deux sequences pour les hypersignaux de la substance blanche profonde. Les atteintes periventriculaires sont fortement correles avec l’etat neurocognitif (p = 0.007), avec une relation lineaire entre l’etendue des anomalies et la severite de l’atteinte neurocognitive (p = 0.01 pour le test de Grober et Buschke). En revanche, les hypersignaux de la substance blanche profonde ne sont pas significativement correles avec l’atteinte cognitive. Conclusion Chez ces sujets « normaux », l’etat neurocognitif semble correle avec l’atteinte de la substance blanche periventriculaire. La sequence FLAIR apparait plus sensible et devait etre integree dans les echelles de gradation de la leucoaraiose.

Published
2004
Full Text
View/download PDF

6. Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications

Author

Rovaris, M., Comi, G., Rocca, M. A., Wolinsky, J. S., Filippi, M., Guillaume, D., D Harcour, J. B., Sindic, C. J. M., Thierry Duprez, Truyen, L., Nagels, G., Parizel, P. M., Sanders, E. A. C. M., Versteylen, R. J., Rice, G., Kennedy, K., Metz, L., Patry, D., Yeung, M., Davis, A., Curtis, S., Francis, G., Arnold, D. L., Leroux, G., Lyon-Caen, O., Tourbah, A., Bataillard, M., Kraehenbuhl, I. R., Cabanis, E. A., Bracard, S., Debouverie, M., Anxionnat, R., Storch-Hagenlocher, B., Sartor, K., Gehlen, W., Schmidt, A., Weiller, C., Behrendt, W., Zaffaroni, M., Fieschi, C., Bastianello, S., Capra, R., Gasparotti, R., Mancardi, G. L., Inglese, M., Sardanelli, F., Cosi, V., Uggetti, C., Zappoli, F., Hawkins, C. P., Haq, N., Barnes, D., Clifton, A., Bates, D., Coulthard, A., Perkin, G., Colquhoun, I., Young, C. A., Nixon, T., Francis, D., Yates, D., Neary, D., Jackson, A., Blumhardt, L. D., Jaspan, T., Brenner, R., Valentine, A., Pye, I., and Cherryman, G.

7. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis

Author

Rovaris, M., Comi, G., Ladkani, D., Wolinsky, J. S., Filippi, M., Guillaume, D., D Harcour, J. B., Sindic, C. J. M., Duprez, T. P. J., Truyen, L., Nagels, G., Parizel, P. M., Sanders, E. A. C. M., Versteylen, R. J., Rice, G., Kennedy, K., Metz, L., Patry, D., Yeung, M., Davis, A., Curtis, S., Francis, G., Arnold, D. L., Leroux, G., Lyon-Caen, O., Tourbah, A., Bataillard, M., Kraehenbuhl, I. R., Cabanis, E. A., Bracard, S., Debouverie, M., Anxionnat, R., Storch-Hagenlocher, B., Sartor, K., Gehlen, W., Schmidt, A., Weiller, C., Behrendt, W., Ghezzi, A., Fieschi, C., Bastianello, S., Capra, R., Gasparotti, R., Mancardi, G. L., Inglese, M., Sardanelli, F., Cosi, V., Uggetti, C., Zappoli, F., Hawkins, C. P., Haq, N., Barnes, D., Clifton, A., Bates, D., Coulthard, A., Perkin, G., Colquhoun, I., Young, C. A., Nixon, T., Francis, D., Yates, D., Neary, D., Jackson, A., Blumhardt, L. D., Jaspan, T., Brenner, R., Valentine, A., Pye, I., Cherryman, G., Barkhof, F., Horsfield, M. A., Johnson, K. P., Hommes, O., Feigin, P., Stark, Y., Michael Gurevich, Kadosh, S., Zak, B., and Pinchassi, I.

8. Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications

Author

Rovaris, M., Comi, G., Rocca, M. A., Wolinsky, J. S., Filippi, M., Guillaume, D., D Harcour, J. B., Sindic, C. J. M., Duprez, T. P. J., Truyen, L., Nagels, G., Parizel, P. M., Sanders, E. A. C. M., Versteylen, R. J., Rice, G., Kennedy, K., Metz, L., Patry, D., Yeung, M., Davis, A., Curtis, S., Francis, G., Arnold, D. L., Leroux, G., Lyon-Caen, O., Tourbah, A., Bataillard, M., Kraehenbuhl, I. R., Cabanis, E. A., Bracard, S., Debouverie, M., Anxionnat, R., Storch-Hagenlocher, B., Sartor, K., Gehlen, W., Schmidt, A., Weiller, C., Behrendt, W., Zaffaroni, M., Fieschi, C., Bastianello, S., Capra, R., Gasparotti, R., Mancardi, G. L., Matilde Inglese, Sardanelli, F., Cosi, V., Uggetti, C., Zappoli, F., Hawkins, C. P., Haq, N., Barnes, D., Clifton, A., Bates, D., Coulthard, A., Perkin, G., Colquhoun, I., Young, C. A., Nixon, T., Francis, D., Yates, D., Neary, D., Jackson, A., Blumhardt, L. D., Jaspan, T., Brenner, R., Valentine, A., Pye, I., and Cherryman, G.

Catalog

Books, media, physical & digital resources
See catalog results